Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
ICD-10 F13.951 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations.
F13.951 refers to a condition characterized by the use of sedative, hypnotic, or anxiolytic substances that leads to a psychotic disorder with hallucinations. This diagnosis is often seen in individuals who misuse these substances, which can include benzodiazepines, barbiturates, and other sedatives. The psychotic disorder manifests as hallucinations, which can be auditory, visual, or tactile, and may significantly impair the individual's ability to function. The condition is classified as 'unspecified' when the specific substance used is not documented, making it crucial for healthcare providers to accurately record the type of substance involved. Treatment typically involves a combination of detoxification, psychiatric support, and rehabilitation programs aimed at addressing both the substance use disorder and the psychotic symptoms. Understanding the interplay between substance use and mental health is essential for effective management and recovery.
Detailed psychiatric evaluations and treatment plans must be documented, including the nature of hallucinations and substance use history.
Patients presenting with acute psychosis following sedative use, or those in withdrawal experiencing hallucinations.
Psychiatrists must differentiate between substance-induced psychosis and other psychiatric disorders.
Comprehensive substance use assessments and treatment progress notes are essential.
Patients undergoing detoxification who exhibit psychotic symptoms related to sedative use.
Focus on the integration of mental health and addiction treatment strategies.
Used for follow-up visits for patients with substance use disorders and psychotic symptoms.
Document the patient's history, mental status examination, and treatment plan.
Psychiatrists should ensure comprehensive assessments are included.
The 'unspecified' designation indicates that the specific sedative, hypnotic, or anxiolytic used is not documented. This can complicate treatment and management, as different substances may have varying effects and withdrawal symptoms.
